Publications

Publications in PubMed
2020
  • Austin R, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Grasel J, Lansink L, Cooper L, Lee S, Chen N, Lee CW, Haque A, Heidel F, D’Andrea R, Hill G, Mullally A, Milsom M, Bywater M, Lane SW. Distinct Effects of Ruxolitinib and Interferon-Alpha on Murine JAK2V617F Myeloproliferative Neoplasm Hematopoietic Stem Cell Populations. Leukemia. 2020 Apr;34(4):1075-89. PMID: 31732720.
  • Marneth AE, Mullally A. The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harb Perspect Med. 2020 Feb 3; 10(2).
  • Mullally A. Both Sides Now: Loss and Gains of Mutant CALR. Blood 2020. Jan 9;135(2):82-83.
  • Mullally A, Hood J, Harrison CN, Mesa R. Fedratinib in Myelofibrosis. Blood Advances 2020. In Press.
2019
  • How J, Hobbs G, Mullally A. Mutant Calreticulin in Myeloproliferative Neoplasms. Blood 2019. Dec 19;134(25):2242-8.
2018
  • Abdelfattah NS, Mullally A. Using CRISPR/Cas9 to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells. J Vis Exp. 2018 Jan 5;131: e56726.
  • Ciboddo M, Mullally A. JAK2 (And Other Genes) Be Nimble With MPN Diagnosis, Prognosis and Therapy. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):110-117.
  • Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally A. Defining the Requirements for the Pathogenic Interaction Between Mutant Calreticulin and MPL in MPN. Blood. 2018 Feb 15;131(7):782-786.
  • Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA. The Kinases IKBKE and TBK1 Regulate MYC-Dependent Survival Pathways Through YB-1 in AML and Are Targets for Therapy. Blood Adv. 2018 Dec 11;2(23):3428-3442.
  • Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, Deangelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL. Increased Neutrophil Extracellular Trap Formation Promotes Thrombosis in Myeloproliferative Neoplasms. Sci Transl Med. 2018 Apr 11;10(436). Pii: eaan8292.
  • Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 Mutational Status Correlates With Distinct Histological Features in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Haematologica. 2018 Feb;103(2):e63-e68.
2017
  • Hobbs SG, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 Aug;31(4):613-626.
  • Rebekka K. Schneider, Ann Mullally, Aurelien Dugourd, Fabian Peisker, Remco Hoogenboezem, Paulina M.H. Van Strien, Eric M. Bindels, Dirk Heckl, Guntram Büsche, David Fleck, Gerhard Müller-Newen,Janewit Wongboonsin, Monica Ventura Ferreira, Victor G. Puelles Et Al. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.  Cell Stem Cell 2017 Jun 1;20(6):785-800. 28457748
  • Mead, Adam J., and Ann Mullally. Myeloproliferative Neoplasm Stem Cells. Blood 2017 Mar 23;129(12):1607-16. 28159736
2016
  • Mullally, A. Underlying Mechanisms of the JAK2V617F Mutation in the Pathogenesis of Myeloproliferative Neoplasms. Pathologe (2016) 37: 175.  27796499
  • Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr; 6(4):368-81. 26951227
  • Esther A. Obeng, Ryan J. Chappell, Michael Seiler, Michelle C. Chen, Dean R. Campagna, Paul J. Schmidt, Rebekka K. Schneider, Allegra M. Lord, Lili Wang, Rutendo G. Gambe, Marie E. McConkey, Abdullah M. Ali, Azra Raza, Lihua Yu, Silvia Buonamici, Peter G. Smith, Ann Mullally, Catherine J. Wu, Mark D. Fleming, Benjamin L. Ebert.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 Sep 12;30(3):404-17. 27622333
2015
  • Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A. RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Rep. 2015 Dec 22; 13(11):2345-52. 26686625
  • Jeremy Wen Q, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80. 26569382
  • Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016 Feb; 172(3):412-9. 26537747
  • Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015 Mar 5; 125(10):1548-52. 25573993
  • Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica. 2015 Apr; 100(4):439-51. 25552701
  • Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015 Feb 5; 125(6):1014-24. 25468568
2014
  • Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program. 2014 Dec 5; 2014(1):268-76. 25696866
  • Lane SW, Mullally A. Hit the spleen, JAK! Blood. 2014 Nov 6; 124(19):2898-900. 25377558
  • Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15190-5. 25288776
  • Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015 Jan 8; 125(2):327-35. 25281607
  • Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20. 25242043
  • De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One. 2014; 9(5):e96209. 24788138
  • Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014 Apr 7; 211(4):605-12. 24616378
2013
  • Mullally A, Ebert BL. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell. 2013 Sep 5;13(3):257-8. 24012363
  • Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Paine Kuhn C, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera. Blood. 2013 Mar 13. 23487027
2004-2012
  • Mullally A, Ebert BL.Janus reveals another face: the biologic rationale for targeting janus kinase 2 in lymphoma. J Clin Oncol. 2012 Nov 20;30(33):4168-70. 22965959
  • Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am. 2012 Oct;26(5):1065-81. 23009938
  • Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gonen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 6;489(7414):155-9. 22820254
  • Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012 Jul 5;120(1):166-72. 22627765
  • Mullally A, Ebert BL. STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell. 2010 Nov 16;18(5):405-6. 21075304
  • Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20;28(24):e409-11. 20530270
  • Mullally A, Ebert BL. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res. 2010 Aug 15;16(16):4074-6. 20587590
  • Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010 Jun 15;17(6):584-96. 20541703
  • Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS,Ebert BL, Kantarjian HM,Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 2;114(1):144-7. 19420352
  • Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr;41(4):455-9. 19287384
  • Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007 Feb 15;109(4):1355-62. Review. 17008540
  • Mullally AM, Vogelsang GB, Moliterno AR. Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004 Dec;18(4):227-34. Review. 15501551
Back To Top